{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:09:50Z","timestamp":1792624190217,"version":"4.5.0"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1038\/nrneurol.2011.63","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T09:57:48Z","timestamp":1307527068000},"page":"343-354","source":"Crossref","is-referenced-by-count":175,"title":["Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis"],"prefix":"10.1038","volume":"7","author":[{"given":"Andrew L.","family":"Mammen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,8]]},"reference":[{"key":"BFnrneurol201163_CR1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292, 403\u2013407 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201163_CR2","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(03)14368-1","volume":"362","author":"MC Dalakas","year":"2003","unstructured":"Dalakas, M. C. & Hohlfeld, R. Polymyositis and dermatomyositis. Lancet 362, 971\u2013982 (2003).","journal-title":"Lancet"},{"key":"BFnrneurol201163_CR3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1749-6632.2009.05119.x","volume":"1184","author":"AL Mammen","year":"2010","unstructured":"Mammen, A. L. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann. NY Acad. Sci. 1184, 134\u2013153 (2010).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol201163_CR4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1136\/jnnp.73.4.420","volume":"73","author":"T Miller","year":"2002","unstructured":"Miller, T., Al-Lozi, M. T., Lopate, G. & Pestronk, A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J. Neurol. Neurosurg. Psychiatry 73, 420\u2013428 (2002).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrneurol201163_CR5","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1212\/WNL.41.6.936","volume":"41","author":"AM Emslie-Smith","year":"1991","unstructured":"Emslie-Smith, A. M. & Engel, A. G. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 41, 936\u2013939 (1991).","journal-title":"Neurology"},{"key":"BFnrneurol201163_CR6","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1212\/WNL.50.3.764","volume":"50","author":"MI Levin","year":"1998","unstructured":"Levin, M. I., Mozaffar, T., Al-Lozi, M. T. & Pestronk, A. Paraneoplastic necrotizing myopathy: clinical and pathological features. Neurology 50, 764\u2013767 (1998).","journal-title":"Neurology"},{"key":"BFnrneurol201163_CR7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF00328515","volume":"236","author":"M Vosskamper","year":"1989","unstructured":"Vosskamper, M., Korf, B., Franke, F. & Schachenmayr, W. Paraneoplastic necrotizing myopathy: a rare disorder to be differentiated from polymyositis. J. Neurol. 236, 489\u2013490 (1989).","journal-title":"J. Neurol."},{"key":"BFnrneurol201163_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","volume":"41","author":"P Grable-Esposito","year":"2010","unstructured":"Grable-Esposito, P. et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41, 185\u2013190 (2010).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201163_CR9","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","volume":"62","author":"L Christopher-Stine","year":"2010","unstructured":"Christopher-Stine, L. et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum. 62, 2757\u20132766 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR10","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","volume":"14","author":"JE Hoogendijk","year":"2004","unstructured":"Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 1\u201312 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337\u2013345 (2004).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol201163_CR11","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ncpneuro0261","volume":"2","author":"MC Dalakas","year":"2006","unstructured":"Dalakas, M. C. Sporadic inclusion body myositis\u2014diagnosis, pathogenesis and therapeutic strategies. Nat. Clin. Pract. Neurol. 2, 437\u2013447 (2006).","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"BFnrneurol201163_CR12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/WCO.0b013e32833d3897","volume":"23","author":"CC Weihl","year":"2010","unstructured":"Weihl, C. C. & Pestronk, A. Sporadic inclusion body myositis: possible pathogenesis inferred from biomarkers. Curr. Opin. Neurol. 23, 482\u2013488 (2010).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrneurol201163_CR13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mus.21386","volume":"40","author":"M Salajegheh","year":"2009","unstructured":"Salajegheh, M. et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 40, 19\u201331 (2009).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201163_CR14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ana.21622","volume":"65","author":"G Karpati","year":"2009","unstructured":"Karpati, G. & O'Ferrall, E. K. Sporadic inclusion body myositis: pathogenic considerations. Ann. Neurol. 65, 7\u201311 (2009).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201163_CR15","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s11926-010-0102-5","volume":"12","author":"SA Greenberg","year":"2010","unstructured":"Greenberg, S. A. Theories of the pathogenesis of inclusion body myositis. Curr. Rheumatol. Rep. 12, 221\u2013228 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneurol201163_CR16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00005792-197707000-00001","volume":"56","author":"A Bohan","year":"1977","unstructured":"Bohan, A., Peter, J. B., Bowman, R. L. & Pearson, C. M. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis. Medicine (Baltimore) 56, 255\u2013286 (1977).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneurol201163_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1080\/08916930600623767","volume":"39","author":"P Mielnik","year":"2006","unstructured":"Mielnik, P., Wiesik-Szewczyk, E., Olesinska, M., Chwalinska-Sadowska, H. & Zabek, J. Clinical features and prognosis of patients with idiopathic myopathies and anti-Jo-1 antibodies. Autoimmunity 39, 243\u2013247 (2006).","journal-title":"Autoimmunity"},{"key":"BFnrneurol201163_CR18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/mus.880020103","volume":"2","author":"EW Streib","year":"1979","unstructured":"Streib, E. W., Wilbourn, A. J. & Mitsumoto, H. Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve 2, 14\u201318 (1979).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201163_CR19","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1212\/WNL.57.11.2136","volume":"57","author":"E Gallardo","year":"2001","unstructured":"Gallardo, E. et al. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology 57, 2136\u20132138 (2001).","journal-title":"Neurology"},{"key":"BFnrneurol201163_CR20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0889-857X(02)00030-3","volume":"28","author":"MC Dalakas","year":"2002","unstructured":"Dalakas, M. C. Muscle biopsy findings in inflammatory myopathies. Rheum. Dis. Clin. North Am. 28, 779\u2013798 (2002).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrneurol201163_CR21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/ana.410190203","volume":"19","author":"K Arahata","year":"1986","unstructured":"Arahata, K. & Engel, A. G. Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann. Neurol. 19, 112\u2013125 (1986).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201163_CR22","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","volume":"325","author":"MC Dalakas","year":"1991","unstructured":"Dalakas, M. C. Polymyositis, dermatomyositis and inclusion-body myositis. N. Engl. J. Med. 325, 1487\u20131498 (1991).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201163_CR23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/0049-0172(86)90014-4","volume":"15","author":"MC Hochberg","year":"1986","unstructured":"Hochberg, M. C., Feldman, D. & Stevens, M. B. Adult onset polymyositis\/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin. Arthritis Rheum. 15, 168\u2013178 (1986).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrneurol201163_CR24","first-page":"2366","volume":"28","author":"JD Carter","year":"2001","unstructured":"Carter, J. D., Kanik, K. S., Vasey, F. B. & Valeriano-Marcet, J. Dermatomyositis with normal creatine kinase and elevated aldolase levels. J. Rheumatol. 28, 2366\u20132367 (2001).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR25","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","volume":"52","author":"S Sato","year":"2005","unstructured":"Sato, S. et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571\u20131576 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/jnnp.2008.161448","volume":"80","author":"K Nozaki","year":"2009","unstructured":"Nozaki, K. & Pestronk, A. High aldolase with normal creatine kinase in serum predicts a myopathy with perimysial pathology. J. Neurol. Neurosurg. Psychiatry. 80, 904\u2013908 (2009).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"BFnrneurol201163_CR27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1177\/0883073808314365","volume":"23","author":"XQ Rosales","year":"2008","unstructured":"Rosales, X. Q. et al. Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage. J. Child Neurol. 23, 748\u2013751 (2008).","journal-title":"J. Child Neurol."},{"key":"BFnrneurol201163_CR28","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiographics.15.3.7624563","volume":"15","author":"EM Adams","year":"1995","unstructured":"Adams, E. M., Chow, C. K., Premkumar, A. & Plotz, P. H. The idiopathic inflammatory myopathies: spectrum of MR imaging findings. Radiographics 15, 563\u2013574 (1995).","journal-title":"Radiographics"},{"key":"BFnrneurol201163_CR29","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","volume":"9","author":"IN Targoff","year":"1997","unstructured":"Targoff, I. N., Miller, F. W., Medsger, T. A. Jr & Oddis, C. V. Classification criteria for the idiopathic inflammatory myopathies. Curr. Opin. Rheumatol. 9, 527\u2013535 (1997).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneurol201163_CR30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan, A. & Peter, J. B. Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292, 344\u2013347 (1975).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201163_CR31","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2214\/ajr.165.6.7484589","volume":"165","author":"ME Schweitzer","year":"1995","unstructured":"Schweitzer, M. E. & Fort, J. Cost-effectiveness of MR imaging in evaluating polymyositis. AJR Am. J. Roentgenol. 165, 1469\u20131471 (1995).","journal-title":"AJR Am. J. Roentgenol."},{"key":"BFnrneurol201163_CR32","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/rheumatology\/kem088","volume":"46","author":"J Tomasova Studynkova","year":"2007","unstructured":"Tomasova Studynkova, J., Charvat, F., Jarosova, K. & Vencovsky, J. The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology (Oxford) 46, 1174\u20131179 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR33","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1749-6632.2009.04386.x","volume":"1154","author":"RV Curiel","year":"2009","unstructured":"Curiel, R. V., Jones, R. & Brindle, K. Magnetic resonance imaging of the idiopathic inflammatory myopathies: structural and clinical aspects. Ann. NY Acad. Sci. 1154, 101\u2013114 (2009).","journal-title":"Ann. NY Acad. Sci."},{"key":"BFnrneurol201163_CR34","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","volume":"355","author":"JP Callen","year":"2000","unstructured":"Callen, J. P. Dermatomyositis. Lancet 355, 53\u201357 (2000).","journal-title":"Lancet"},{"key":"BFnrneurol201163_CR35","first-page":"2","volume":"15","author":"EM Dugan","year":"2009","unstructured":"Dugan, E. M., Huber, A. M., Miller, F. W., Rider, L. G. & International Myositis Assessment and Clinical Studies Group. Review of the classification and assessment of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol. Online J. 15, 2 (2009).","journal-title":"Dermatol. Online J."},{"key":"BFnrneurol201163_CR36","first-page":"1","volume":"15","author":"EM Dugan","year":"2009","unstructured":"Dugan, E. M., Huber, A. M., Miller, F. W., Rider, L. G. & International Myositis Assessment and Clinical Studies Group. Photoessay of the cutaneous manifestations of the idiopathic inflammatory myopathies. Dermatol. Online J. 15, 1 (2009).","journal-title":"Dermatol. Online J."},{"key":"BFnrneurol201163_CR37","doi-asserted-by":"crossref","first-page":"124S","DOI":"10.1038\/jid.1993.35","volume":"100","author":"RL Euwer","year":"1993","unstructured":"Euwer, R. L. & Sontheimer, R. D. Amyopathic dermatomyositis: a review. J. Invest. Dermatol. 100, 124S\u2013127S (1993).","journal-title":"J. Invest. Dermatol."},{"key":"BFnrneurol201163_CR38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2133.1994.tb08492.x","volume":"131","author":"WK Cheong","year":"1994","unstructured":"Cheong, W. K., Hughes, G. R., Norris, P. G. & Hawk, J. L. Cutaneous photosensitivity in dermatomyositis. Br. J. Dermatol. 131, 205\u2013208 (1994).","journal-title":"Br. J. Dermatol."},{"key":"BFnrneurol201163_CR39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1600-0781.2004.00115.x","volume":"20","author":"L Dourmishev","year":"2004","unstructured":"Dourmishev, L., Meffert, H. & Piazena, H. Dermatomyositis: comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol. Photoimmunol. Photomed. 20, 230\u2013234 (2004).","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"BFnrneurol201163_CR40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5858\/2008-132-652-ID","volume":"132","author":"AN Crowson","year":"2008","unstructured":"Crowson, A. N., Magro, C. M. & Mihm, M. C. Jr. Interface dermatitis. Arch. Pathol. Lab. Med. 132, 652\u2013666 (2008).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"BFnrneurol201163_CR41","first-page":"45","volume":"15","author":"LA Dourmishev","year":"2006","unstructured":"Dourmishev, L. A. & Wollina, U. Dermatomyositis: immunopathologic study of skin lesions. Acta Dermatovenerol. Alp. Panonica Adriat. 15, 45\u201351 (2006).","journal-title":"Acta Dermatovenerol. Alp. Panonica Adriat."},{"key":"BFnrneurol201163_CR42","first-page":"512","volume":"5","author":"MG Cohen","year":"1986","unstructured":"Cohen, M. G., Nash, P. & Webb, J. Calcification is rare in adult-onset dermatopolymyositis. Clin. Rheumatol. 5, 512\u2013516 (1986).","journal-title":"Clin. Rheumatol."},{"key":"BFnrneurol201163_CR43","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0733-8619(05)70337-6","volume":"15","author":"AA Amato","year":"1997","unstructured":"Amato, A. A. & Barohn, R. J. Idiopathic inflammatory myopathies. Neurol. Clin. 15, 615\u2013648 (1997).","journal-title":"Neurol. Clin."},{"key":"BFnrneurol201163_CR44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/0002-8703(93)90075-K","volume":"125","author":"WP Follansbee","year":"1993","unstructured":"Follansbee, W. P., Zerbe, T. R. & Medsger, T. A. Jr. Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am. Heart J. 125, 194\u2013203 (1993).","journal-title":"Am. Heart J."},{"key":"BFnrneurol201163_CR45","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ard.28.3.281","volume":"28","author":"JM Thompson","year":"1969","unstructured":"Thompson, J. M., Bluestone, R., Bywaters, E. G., Dorling, J. & Johnson, M. Skeletal muscle involvement in systemic sclerosis. Ann. Rheum. Dis. 28, 281\u2013288 (1969).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR46","first-page":"1140","volume":"12","author":"KE Tymms","year":"1985","unstructured":"Tymms, K. E. & Webb, J. Dermatopolymyositis and other connective tissue diseases: a review of 105 cases. J. Rheumatol. 12, 1140\u20131148 (1985).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR47","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0307-742X(21)00488-4","volume":"10","author":"AD Askari","year":"1984","unstructured":"Askari, A. D. Inflammatory disorders of muscle. Cardiac abnormalities. Clin. Rheum. Dis. 10, 131\u2013149 (1984).","journal-title":"Clin. Rheum. Dis."},{"key":"BFnrneurol201163_CR48","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/0002-9149(78)90871-8","volume":"41","author":"JS Gottdiener","year":"1978","unstructured":"Gottdiener, J. S., Sherber, H. S., Hawley, R. J. & Engel, W. K. Cardiac manifestations in polymyositis. Am. J. Cardiol. 41, 1141\u20131149 (1978).","journal-title":"Am. J. Cardiol."},{"key":"BFnrneurol201163_CR49","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/0002-9149(82)90408-8","volume":"50","author":"HM Haupt","year":"1982","unstructured":"Haupt, H. M. & Hutchins, G. M. The heart and cardiac conduction system in polymyositis-dermatomyositis: a clinicopathologic study of 16 autopsied patients. Am. J. Cardiol. 50, 998\u20131006 (1982).","journal-title":"Am. J. Cardiol."},{"key":"BFnrneurol201163_CR50","first-page":"459","volume":"10","author":"SL Strongwater","year":"1983","unstructured":"Strongwater, S. L., Annesley, T. & Schnitzer, T. J. Myocardial involvement in polymyositis. J. Rheumatol. 10, 459\u2013463 (1983).","journal-title":"J. Rheumatol."},{"issue":"Suppl. 4","key":"BFnrneurol201163_CR51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/rheumatology\/kel311","volume":"45","author":"IE Lundberg","year":"2006","unstructured":"Lundberg, I. E. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 45 (Suppl. 4), 18\u201321 (2006).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR52","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1001\/archinte.1984.04400020097015","volume":"144","author":"R Stern","year":"1984","unstructured":"Stern, R., Godbold, J. H., Chess, Q. & Kagen, L. J. ECG abnormalities in polymyositis. Arch. Intern. Med. 144, 2185\u20132189 (1984).","journal-title":"Arch. Intern. Med."},{"key":"BFnrneurol201163_CR53","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/0049-0172(84)90010-6","volume":"14","author":"BF Dickey","year":"1984","unstructured":"Dickey, B. F. & Myers, A. R. Pulmonary disease in polymyositis\/dermatomyositis. Semin. Arthritis Rheum. 14, 60\u201376 (1984).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrneurol201163_CR54","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1378\/chest.65.4.403","volume":"65","author":"AR Frazier","year":"1974","unstructured":"Frazier, A. R. & Miller, R. D. Interstitial pneumonitis in association with polymyositis and dermatomyositis. Chest 65, 403\u2013407 (1974).","journal-title":"Chest"},{"key":"BFnrneurol201163_CR55","first-page":"723","volume":"129","author":"S Park","year":"1975","unstructured":"Park, S. & Nyhan, W. L. Fatal pulmonary involvement in dermatomyositis. Am. J. Dis. Child. 129, 723\u2013726 (1975).","journal-title":"Am. J. Dis. Child."},{"key":"BFnrneurol201163_CR56","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00005792-197601000-00005","volume":"55","author":"MI Schwarz","year":"1976","unstructured":"Schwarz, M. I. et al. Interstitial lung disease in polymyositis and dermatomyositis: analysis of six cases and review of the literature. Medicine (Baltimore) 55, 89\u2013104 (1976).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneurol201163_CR57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/art.1780280303","volume":"28","author":"J Benbassat","year":"1985","unstructured":"Benbassat, J. et al. Prognostic factors in polymyositis\/dermatomyositis. A computer-assisted analysis of ninety-two cases. Arthritis Rheum. 28, 249\u2013255 (1985).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/ajrccm\/141.3.727","volume":"141","author":"HD Tazelaar","year":"1990","unstructured":"Tazelaar, H. D., Viggiano, R. W., Pickersgill, J. & Colby, T. V. Interstitial lung disease in polymyositis and dermatomyositis. Clinical features and prognosis as correlated with histologic findings. Am. Rev. Respir. Dis. 141, 727\u2013733 (1990).","journal-title":"Am. Rev. Respir. Dis."},{"key":"BFnrneurol201163_CR59","first-page":"102","volume":"14","author":"H Takizawa","year":"1987","unstructured":"Takizawa, H. et al. Interstitial lung disease in dermatomyositis: clinicopathological study. J. Rheumatol. 14, 102\u2013107 (1987).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR60","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/ard.2003.006122","volume":"63","author":"M Fathi","year":"2004","unstructured":"Fathi, M., Dastmalchi, M., Rasmussen, E., Lundberg, I. E. & Tornling, G. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann. Rheum. Dis. 63, 297\u2013301 (2004).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR61","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/rheumatology\/kep078","volume":"48","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena, H., Betteridge, Z. E. & McHugh, N. J. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 48, 607\u2013612 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR62","first-page":"668","volume":"22","author":"K Tanimoto","year":"1995","unstructured":"Tanimoto, K. et al. Classification criteria for polymyositis and dermatomyositis. J. Rheumatol. 22, 668\u2013674 (1995).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR63","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2230.2009.03227.x","volume":"34","author":"V Madan","year":"2009","unstructured":"Madan, V., Chinoy, H., Griffiths, C. E. & Cooper, R. G. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin. Exp. Dermatol. 34, 561\u2013565 (2009).","journal-title":"Clin. Exp. Dermatol."},{"key":"BFnrneurol201163_CR64","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/art.1780230802","volume":"23","author":"M Nishikai","year":"1980","unstructured":"Nishikai, M. & Reichlin, M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881\u2013888 (1980).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR65","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2169\/internalmedicine.44.527","volume":"44","author":"M Hirakata","year":"2005","unstructured":"Hirakata, M. Autoantibodies to aminoacyl-tRNA synthetases. Intern. Med. 44, 527\u2013528 (2005).","journal-title":"Intern. Med."},{"key":"BFnrneurol201163_CR66","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1084\/jem.160.2.420","volume":"160","author":"MB Mathews","year":"1984","unstructured":"Mathews, M. B., Reichlin, M., Hughes, G. R. & Bernstein, R. M. Anti-threonyl-tRNA synthetase, a second myositis-related autoantibody. J. Exp. Med. 160, 420\u2013434 (1984).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol201163_CR67","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1084\/jem.163.5.1281","volume":"163","author":"CC Bunn","year":"1986","unstructured":"Bunn, C. C., Bernstein, R. M. & Mathews, M. B. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J. Exp. Med. 163, 1281\u20131291 (1986).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol201163_CR68","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.4049\/jimmunol.144.5.1737","volume":"144","author":"IN Targoff","year":"1990","unstructured":"Targoff, I. N. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J. Immunol. 144, 1737\u20131743 (1990).","journal-title":"J. Immunol."},{"key":"BFnrneurol201163_CR69","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.4049\/jimmunol.162.4.2315","volume":"162","author":"M Hirakata","year":"1999","unstructured":"Hirakata, M. et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J. Immunol. 162, 2315\u20132320 (1999).","journal-title":"J. Immunol."},{"issue":"Suppl.","key":"BFnrneurol201163_CR70","first-page":"S312","volume":"52","author":"L Hashish","year":"2005","unstructured":"Hashish, L., Trieu, E. P., Sadanandan, P. & Targoff, I. N. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome (abstract). Arthritis Rheum. 52 (Suppl.), S312 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR71","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/rheumatology\/kem045","volume":"46","author":"Z Betteridge","year":"2007","unstructured":"Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 46, 1005\u20131008 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR72","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.1780260505","volume":"26","author":"S Yoshida","year":"1983","unstructured":"Yoshida, S. et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 26, 604\u2013611 (1983).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR73","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","volume":"77","author":"C Marguerie","year":"1990","unstructured":"Marguerie, C. et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q. J. Med. 77, 1019\u20131038 (1990).","journal-title":"Q. J. Med."},{"key":"BFnrneurol201163_CR74","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1378\/chest.08-2233","volume":"135","author":"M Kalluri","year":"2009","unstructured":"Kalluri, M. et al. Clinical profile of anti-PL-12 autoantibody: Cohort study and review of the literature. Chest 135, 1550\u20131556 (2009).","journal-title":"Chest"},{"key":"BFnrneurol201163_CR75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","volume":"5","author":"M Reichlin","year":"1976","unstructured":"Reichlin, M. & Mattioli, M. Description of a serological reaction characteristic of polymyositis. Clin. Immunol. Immunopathol. 5, 12\u201320 (1976).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFnrneurol201163_CR76","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/art.1780381006","volume":"38","author":"HP Seelig","year":"1995","unstructured":"Seelig, H. P. et al. The major dermatomyositis-specific Mi-2 autoantigen is a presumed helicase involved in transcriptional activation. Arthritis Rheum. 38, 1389\u20131399 (1995).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR77","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/art.1780391029","volume":"39","author":"HP Seelig","year":"1996","unstructured":"Seelig, H. P., Renz, M., Targoff, I. N., Ge, Q. & Frank, M. B. Two forms of the major antigenic protein of the dermatomyositis-specific Mi-2 autoantigen. Arthritis Rheum. 39, 1769\u20131771 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR78","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1172\/JCI118218","volume":"96","author":"Q Ge","year":"1995","unstructured":"Ge, Q., Nilasena, D. S., O'Brien, C. A., Frank, M. B. & Targoff, I. N. Molecular analysis of a major antigenic region of the 240-kD protein of Mi-2 autoantigen. J. Clin. Invest. 96, 1730\u20131737 (1995).","journal-title":"J. Clin. Invest."},{"key":"BFnrneurol201163_CR79","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/art.1780380119","volume":"38","author":"DS Nilasena","year":"1995","unstructured":"Nilasena, D. S., Trieu, E. P. & Targoff, I. N. Analysis of the Mi-2 autoantigen of dermatomyositis. Arthritis Rheum. 38, 123\u2013128 (1995).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR80","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0092-8674(00)81758-4","volume":"95","author":"Y Zhang","year":"1998","unstructured":"Zhang, Y., LeRoy, G., Seelig, H. P., Lane, W. S. & Reinberg, D. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95, 279\u2013289 (1998).","journal-title":"Cell"},{"key":"BFnrneurol201163_CR81","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1093\/nar\/29.12.2517","volume":"29","author":"HB Wang","year":"2001","unstructured":"Wang, H. B. & Zhang, Y. Mi2, an auto-antigen for dermatomyositis, is an ATP-dependent nucleosome remodeling factor. Nucleic Acids Res. 29, 2517\u20132521 (2001).","journal-title":"Nucleic Acids Res."},{"key":"BFnrneurol201163_CR82","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1242\/dev.001750","volume":"134","author":"M Kashiwagi","year":"2007","unstructured":"Kashiwagi, M., Morgan, B. A. & Georgopoulos, K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 134, 1571\u20131582 (2007).","journal-title":"Development"},{"key":"BFnrneurol201163_CR83","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cell.2004.09.014","volume":"119","author":"N Fujita","year":"2004","unstructured":"Fujita, N. et al. MTA3 and the Mi-2\/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell 119, 75\u201386 (2004).","journal-title":"Cell"},{"key":"BFnrneurol201163_CR84","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.immuni.2004.05.005","volume":"20","author":"CJ Williams","year":"2004","unstructured":"Williams, C. J. et al. The chromatin remodeler Mi-2\u03b2 is required for CD4 expression and T cell development. Immunity 20, 719\u2013733 (2004).","journal-title":"Immunity"},{"key":"BFnrneurol201163_CR85","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.immuni.2007.09.008","volume":"27","author":"T Naito","year":"2007","unstructured":"Naito, T., Gomez-Del Arco, P., Williams, C. J. & Georgopoulos, K. Antagonistic interactions between Ikaros and the chromatin remodeler Mi-2\u03b2 determine silencer activity and Cd4 gene expression. Immunity 27, 723\u2013734 (2007).","journal-title":"Immunity"},{"key":"BFnrneurol201163_CR86","doi-asserted-by":"crossref","first-page":"11258","DOI":"10.1073\/pnas.0809485106","volume":"106","author":"H Gao","year":"2009","unstructured":"Gao, H. et al. Opposing effects of SWI\/SNF and Mi-2\/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. Proc. Natl Acad. Sci. USA 106, 11258\u201311263 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201163_CR87","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.24977","volume":"60","author":"AL Mammen","year":"2009","unstructured":"Mammen, A. L. et al. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 60, 3784\u20133793 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR88","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/08916930400022681","volume":"38","author":"A Ghirardello","year":"2005","unstructured":"Ghirardello, A. et al. Anti-Mi-2 antibodies. Autoimmunity 38, 79\u201383 (2005).","journal-title":"Autoimmunity"},{"key":"BFnrneurol201163_CR89","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","volume":"28","author":"IN Targoff","year":"1985","unstructured":"Targoff, I. N. & Reichlin, M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28, 796\u2013803 (1985).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/s11926-996-0025-3","volume":"8","author":"IN Targoff","year":"2006","unstructured":"Targoff, I. N. Myositis specific autoantibodies. Curr. Rheumatol. Rep. 8, 196\u2013203 (2006).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneurol201163_CR91","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love, L. A. et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70, 360\u2013374 (1991).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneurol201163_CR92","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1002\/art.1780390910","volume":"39","author":"FC Arnett","year":"1996","unstructured":"Arnett, F. C. et al. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 39, 1507\u20131518 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR93","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/art.1780390521","volume":"39","author":"R Mierau","year":"1996","unstructured":"Mierau, R. et al. Strong association of dermatomyositis-specific Mi-2 autoantibodies with a tryptophan at position 9 of the HLA-DR beta chain. Arthritis Rheum. 39, 868\u2013876 (1996).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR94","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1002\/1529-0131(199707)40:7<1257::AID-ART10>3.0.CO;2-R","volume":"40","author":"I Hausmanowa-Petrusewicz","year":"1997","unstructured":"Hausmanowa-Petrusewicz, I. et al. Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. Arthritis Rheum. 40, 1257\u20131266 (1997).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR95","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0889-857X(02)00032-7","volume":"28","author":"IN Targoff","year":"2002","unstructured":"Targoff, I. N. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 28, 859\u2013890 (2002).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"BFnrneurol201163_CR96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1136\/ard.2005.040717","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman, G. J. et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2\u03b2 antigen. Ann. Rheum. Dis. 65, 242\u2013245 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR97","first-page":"395","volume":"25","author":"S Roux","year":"1998","unstructured":"Roux, S., Seelig, H. P. & Meyer, O. Significance of Mi-2 autoantibodies in polymyositis and dermatomyositis. J. Rheumatol. 25, 395\u2013396 (1998).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR98","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1002\/art.22164","volume":"54","author":"IN Targoff","year":"2006","unstructured":"Targoff, I. N. et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54, 3682\u20133689 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR99","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/kel161","volume":"46","author":"K Kaji","year":"2007","unstructured":"Kaji, K. et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 46, 25\u201328 (2007).","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl.","key":"BFnrneurol201163_CR100","first-page":"S518","volume":"55","author":"IN Targoff","year":"2006","unstructured":"Targoff, I. N., Trieu, E., Levy-Neto, M., Prasertsuntarasai, T. & Miller, F. W. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum. 55 (Suppl.), S518 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR101","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1136\/ard.2006.068502","volume":"66","author":"H Chinoy","year":"2007","unstructured":"Chinoy, H., Fertig, N., Oddis, C. V., Ollier, W. E. & Cooper, R. G. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann. Rheum. Dis. 66, 1345\u20131349 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR102","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/rheumatology\/keq153","volume":"49","author":"K Hoshino","year":"2010","unstructured":"Hoshino, K. et al. Anti-MDA5 and anti-TIF1-\u03b3 antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford) 49, 1726\u20131733 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR103","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/rheumatology\/kem359","volume":"47","author":"H Gunawardena","year":"2008","unstructured":"Gunawardena, H. et al. Clinical associations of autoantibodies to a p155\/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 47, 324\u2013328 (2008).","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl.","key":"BFnrneurol201163_CR104","first-page":"S139","volume":"40","author":"CV Oddis","year":"1997","unstructured":"Oddis, C. V. et al. Clinical and serological characterisation of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 40 (Suppl.), S139 (1997).","journal-title":"Arthritis Rheum."},{"issue":"Suppl.","key":"BFnrneurol201163_CR105","first-page":"S787","volume":"56","author":"IN Targoff","year":"2007","unstructured":"Targoff, I. N., Trieu, E. P., Levy-Neto, M., Fertig, N. & Oddis, C. V. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum. 56 (Suppl.), S787 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR106","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/art.24547","volume":"60","author":"H Gunawardena","year":"2009","unstructured":"Gunawardena, H. et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60, 1807\u20131814 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR107","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato, S. et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193\u20132200 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR108","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","volume":"49","author":"T Gono","year":"2010","unstructured":"Gono, T. et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49, 1713\u20131719 (2010).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrneurol201163_CR109","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1002\/art.22862","volume":"56","author":"Z Betteridge","year":"2007","unstructured":"Betteridge, Z., Gunawardena, H., North, J., Slinn, J. & McHugh, N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 56, 3132\u20133137 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR110","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1136\/ard.2008.097162","volume":"68","author":"ZE Betteridge","year":"2009","unstructured":"Betteridge, Z. E. et al. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann. Rheum. Dis. 68, 1621\u20131625 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR111","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1073\/pnas.83.24.9507","volume":"83","author":"WH Reeves","year":"1986","unstructured":"Reeves, W. H., Nigam, S. K. & Blobel, G. Human autoantibodies reactive with the signal-recognition particle. Proc. Natl Acad. Sci. USA 83, 9507\u20139511 (1986).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneurol201163_CR112","first-page":"1727","volume":"32","author":"T Satoh","year":"2005","unstructured":"Satoh, T. et al. Novel autoantibodies against 7SL RNA in patients with polymyositis\/dermatomyositis. J. Rheumatol. 32, 1727\u20131733 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrneurol201163_CR113","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","volume":"33","author":"IN Targoff","year":"1990","unstructured":"Targoff, I. N., Johnson, A. E. & Miller, F. W. Antibody to signal recognition particle in polymyositis. Arthritis Rheum. 33, 1361\u20131370 (1990).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR114","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao, A. H., Lacomis, D., Lucas, M., Fertig, N. & Oddis, C. V. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum. 50, 209\u2013215 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR115","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/s10165-008-0139-8","volume":"19","author":"T Takada","year":"2009","unstructured":"Takada, T. et al. Clinical and histopathological features of myopathies in Japanese patients with anti-SRP autoantibodies. Mod. Rheumatol. 19, 156\u2013164 (2009).","journal-title":"Mod. Rheumatol."},{"key":"BFnrneurol201163_CR116","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1136\/ard.2006.052191","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman, G. J. et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann. Rheum. Dis. 65, 1635\u20131638 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR117","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9149(02)02449-9","volume":"90","author":"PR de Sauvage Nolting","year":"2002","unstructured":"de Sauvage Nolting, P. R., Buirma, R. J., Hutten, B. A., Kastelein, J. J. & Dutch ExPRESS Investigator Group. Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia [ExPRESS FH]). Am. J. Cardiol. 90, 181\u2013184 (2002).","journal-title":"Am. J. Cardiol."},{"key":"BFnrneurol201163_CR118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert, E., Hayem, G., Dejager, S., Yau, C. & Begaud, B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc. Drugs Ther. 19, 403\u2013414 (2005).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"BFnrneurol201163_CR119","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","volume":"17","author":"S Franc","year":"2003","unstructured":"Franc, S. et al. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc. Drugs Ther. 17, 459\u2013465 (2003).","journal-title":"Cardiovasc. Drugs Ther."},{"key":"BFnrneurol201163_CR120","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","volume":"292","author":"DJ Graham","year":"2004","unstructured":"Graham, D. J. et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585\u20132590 (2004).","journal-title":"JAMA"},{"key":"BFnrneurol201163_CR121","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-7843.2006.pto_193.x","volume":"98","author":"K Soininen","year":"2006","unstructured":"Soininen, K., Niemi, M., Kilkki, E., Strandberg, T. & Kivisto, K. T. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin. Pharmacol. Toxicol. 98, 51\u201354 (2006).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"BFnrneurol201163_CR122","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.revmed.2003.10.013","volume":"25","author":"AL Fauchais","year":"2004","unstructured":"Fauchais, A. L. et al. Polymyositis induced or associated with lipid-lowering drugs: five cases. Rev. Med. Interne 25, 294\u2013298 (2004).","journal-title":"Rev. Med. Interne"},{"key":"BFnrneurol201163_CR123","doi-asserted-by":"crossref","first-page":"934","DOI":"10.33588\/rn.3710.2003263","volume":"37","author":"G Riesco-Eizaguirre","year":"2003","unstructured":"Riesco-Eizaguirre, G., Arpa-Gutierrez, F. J., Gutierrez, M. & Toribio, E. Severe polymyositis with simvastatin use. Rev. Neurol. 37, 934\u2013936 (2003).","journal-title":"Rev. Neurol."},{"key":"BFnrneurol201163_CR124","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mus.20127","volume":"30","author":"OM Vasconcelos","year":"2004","unstructured":"Vasconcelos, O. M. & Campbell, W. W. Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake. Muscle Nerve 30, 803\u2013807 (2004).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201163_CR125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","volume":"17","author":"M Needham","year":"2007","unstructured":"Needham, M. et al. Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscul. Disord. 17, 194\u2013200 (2007).","journal-title":"Neuromuscul. Disord."},{"key":"BFnrneurol201163_CR126","first-page":"327","volume":"54","author":"D Rowe","year":"1983","unstructured":"Rowe, D., Isenberg, D. A. & Beverley, P. C. Monoclonal antibodies to human leucocyte antigens in polymyositis and muscular dystrophy. Clin. Exp. Immunol. 54, 327\u2013336 (1983).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrneurol201163_CR127","first-page":"136","volume":"75","author":"J van der Pas","year":"2004","unstructured":"van der Pas, J., Hengstman, G. J., ter Laak, H. J., Borm, G. F. & van Engelen, B. G. Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies. J. Neurol. Neurosurg. Psychiatry. 75, 136\u2013139 (2004).","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"BFnrneurol201163_CR128","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4103\/0028-3886.43457","volume":"56","author":"C Sundaram","year":"2008","unstructured":"Sundaram, C., Uppin, M. S. & Meena, A. K. Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. Neurol. India 56, 363\u2013367 (2008).","journal-title":"Neurol. India"},{"key":"BFnrneurol201163_CR129","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713\u2013721 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR130","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/jcp.21810","volume":"220","author":"C Martini","year":"2009","unstructured":"Martini, C. et al. 3-hydroxy 3-methylglutaryl coenzyme A reductase increase is essential for rat muscle differentiation. J. Cell. Physiol. 220, 524\u2013530 (2009).","journal-title":"J. Cell. Physiol."},{"key":"BFnrneurol201163_CR131","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill, C. L. et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357, 96\u2013100 (2001).","journal-title":"Lancet"},{"key":"BFnrneurol201163_CR132","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.29.1.67","volume":"29","author":"WL Norton","year":"1970","unstructured":"Norton, W. L., Velayos, E. & Robison, L. Endothelial inclusions in dermatomyositis. Ann. Rheum. Dis. 29, 67\u201372 (1970).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrneurol201163_CR133","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/ana.410270402","volume":"27","author":"AM Emslie-Smith","year":"1990","unstructured":"Emslie-Smith, A. M. & Engel, A. G. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann. Neurol. 27, 343\u2013356 (1990).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201163_CR134","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1056\/NEJM198602063140601","volume":"314","author":"JT Kissel","year":"1986","unstructured":"Kissel, J. T., Mendell, J. R. & Rammohan, K. W. Microvascular deposition of complement membrane attack complex in dermatomyositis. N. Engl. J. Med. 314, 329\u2013334 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFnrneurol201163_CR135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archneur.1991.00530130034016","volume":"48","author":"JT Kissel","year":"1991","unstructured":"Kissel, J. T., Halterman, R. K., Rammohan, K. W. & Mendell, J. R. The relationship of complement-mediated microvasculopathy to the histologic features and clinical duration of disease in dermatomyositis. Arch. Neurol. 48, 26\u201330 (1991).","journal-title":"Arch. Neurol."},{"key":"BFnrneurol201163_CR136","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1212\/WNL.26.10.952","volume":"26","author":"S Carpenter","year":"1976","unstructured":"Carpenter, S., Karpati, G., Rothman, S. & Watters, G. The childhood type of dermatomyositis. Neurology 26, 952\u2013962 (1976).","journal-title":"Neurology"},{"key":"BFnrneurol201163_CR137","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0022-510X(89)90228-1","volume":"94","author":"M De Visser","year":"1989","unstructured":"De Visser, M., Emslie-Smith, A. M. & Engel, A. G. Early ultrastructural alterations in adult dermatomyositis. Capillary abnormalities precede other structural changes in muscle. J. Neurol. Sci. 94, 181\u2013192 (1989).","journal-title":"J. Neurol. Sci."},{"key":"BFnrneurol201163_CR138","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1740-2557-3-2","volume":"3","author":"K Nagaraju","year":"2006","unstructured":"Nagaraju, K. et al. Endothelial cell activation and neovascularization are prominent in dermatomyositis. J. Autoimmune Dis. 3, 2 (2006).","journal-title":"J. Autoimmune Dis."},{"key":"BFnrneurol201163_CR139","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.23884","volume":"58","author":"C Grundtman","year":"2008","unstructured":"Grundtman, C., Tham, E., Ulfgren, A. K. & Lundberg, I. E. Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 58, 3224\u20133238 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mus.21651","volume":"42","author":"A Pestronk","year":"2010","unstructured":"Pestronk, A., Schmidt, R. E. & Choksi, R. Vascular pathology in dermatomyositis and anatomic relations to myopathology. Muscle Nerve 42, 53\u201361 (2010).","journal-title":"Muscle Nerve"},{"key":"BFnrneurol201163_CR141","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg, S. A. et al. Interferon-\u03b1\/\u03b2-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664\u2013678 (2005).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201163_CR142","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1126\/science.284.5421.1835","volume":"284","author":"FP Siegal","year":"1999","unstructured":"Siegal, F. P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835\u20131837 (1999).","journal-title":"Science"},{"key":"BFnrneurol201163_CR143","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/j.1600-0560.2007.00848.x","volume":"35","author":"JM McNiff","year":"2008","unstructured":"McNiff, J. M. & Kaplan, D. H. Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J. Cutan. Pathol. 35, 452\u2013456 (2008).","journal-title":"J. Cutan. Pathol."},{"key":"BFnrneurol201163_CR144","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ana.21805","volume":"67","author":"M Salajegheh","year":"2010","unstructured":"Salajegheh, M. et al. Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann. Neurol. 67, 53\u201363 (2010).","journal-title":"Ann. Neurol."},{"key":"BFnrneurol201163_CR145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1600-0560.2009.01443.x","volume":"37","author":"CM Magro","year":"2010","unstructured":"Magro, C. M., Segal, J. P., Crowson, A. N. & Chadwick, P. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J. Cutan. Pathol. 37, 659\u2013671 (2010).","journal-title":"J. Cutan. Pathol."},{"key":"BFnrneurol201163_CR146","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","volume":"12","author":"SA Greenberg","year":"2010","unstructured":"Greenberg, S. A. Dermatomyositis and type 1 interferons. Curr. Rheumatol. Rep. 12, 198\u2013203 (2010).","journal-title":"Curr. Rheumatol. Rep."},{"key":"BFnrneurol201163_CR147","first-page":"638","volume":"52","author":"PM Grimley","year":"1985","unstructured":"Grimley, P. M. et al. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with alpha-interferon. Lab. Invest. 52, 638\u2013649 (1985).","journal-title":"Lab. Invest."},{"key":"BFnrneurol201163_CR148","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/01913128609015565","volume":"10","author":"J Kuyama","year":"1986","unstructured":"Kuyama, J. et al. Formation of tubuloreticular inclusions in mitogen-stimulated human lymphocyte cultures by endogenous or exogenous alpha-interferon. Ultrastruct. Pathol. 10, 77\u201385 (1986).","journal-title":"Ultrastruct. Pathol."},{"key":"BFnrneurol201163_CR149","first-page":"584","volume":"58","author":"D Feldman","year":"1988","unstructured":"Feldman, D., Goldstein, A. L., Cox, D. C. & Grimley, P. M. Cultured human endothelial cells treated with recombinant leukocyte A interferon. Tubuloreticular inclusion formation, antiproliferative effect, and 2\u2032, 5\u2032 oligoadenylate synthetase induction. Lab. Invest. 58, 584\u2013589 (1988).","journal-title":"Lab. Invest."},{"key":"BFnrneurol201163_CR150","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1002\/art.22928","volume":"56","author":"RJ Walsh","year":"2007","unstructured":"Walsh, R. J. et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 56, 3784\u20133792 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR151","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler, E. C. et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol. Med. 13, 59\u201368 (2007).","journal-title":"Mol. Med."},{"key":"BFnrneurol201163_CR152","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1084\/jem.20041367","volume":"201","author":"L Casciola-Rosen","year":"2005","unstructured":"Casciola-Rosen, L. et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J. Exp. Med. 201, 591\u2013601 (2005).","journal-title":"J. Exp. Med."},{"key":"BFnrneurol201163_CR153","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/01.bor.0000245721.02512.77","volume":"18","author":"SM Levine","year":"2006","unstructured":"Levine, S. M. Cancer and myositis: new insights into an old association. Curr. Opin. Rheumatol. 18, 620\u2013624 (2006).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneurol201163_CR154","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ncprheum0760","volume":"4","author":"TL Suber","year":"2008","unstructured":"Suber, T. L., Casciola-Rosen, L. & Rosen, A. Mechanisms of disease: autoantigens as clues to the pathogenesis of myositis. Nat. Clin. Pract. Rheumatol. 4, 201\u2013209 (2008).","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"BFnrneurol201163_CR155","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/BOR.0b013e3283315a22","volume":"21","author":"H Chinoy","year":"2009","unstructured":"Chinoy, H., Lamb, J. A., Ollier, W. E. & Cooper, R. G. An update on the immunogenetics of idiopathic inflammatory myopathies: major histocompatibility complex and beyond. Curr. Opin. Rheumatol. 21, 588\u2013593 (2009).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneurol201163_CR156","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.md.0000217525.82287.eb","volume":"85","author":"TP O'Hanlon","year":"2006","unstructured":"O'Hanlon, T. P. et al. Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1, and -DQA1 allelic profiles distinguish European American patients with different myositis autoantibodies. Medicine (Baltimore) 85, 111\u2013127 (2006).","journal-title":"Medicine (Baltimore)"},{"key":"BFnrneurol201163_CR157","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.bor.0000142339.24380.b7","volume":"16","author":"H Chinoy","year":"2004","unstructured":"Chinoy, H., Ollier, W. E. & Cooper, R. G. Have recent immunogenetic investigations increased our understanding of disease mechanisms in the idiopathic inflammatory myopathies? Curr. Opin. Rheumatol. 16, 707\u2013713 (2004).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrneurol201163_CR158","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199907)42:7<1552::AID-ANR33>3.0.CO;2-K","volume":"42","author":"R Mierau","year":"1999","unstructured":"Mierau, R. et al. An update on HLA association of Mi-2 autoantibodies: the association with a tryptophan at position 9 of the HLA-DRbeta chain is strong but not absolute. Arthritis Rheum. 42, 1552\u20131553 (1999).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR159","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/art.10358","volume":"46","author":"EA Shamim","year":"2002","unstructured":"Shamim, E. A. et al. Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis. Arthritis Rheum. 46, 1885\u20131893 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR160","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1002\/art.23899","volume":"58","author":"TP O'Hanlon","year":"2008","unstructured":"O'Hanlon, T. P. et al. Immunoglobulin gene polymorphisms are susceptibility factors in clinical and autoantibody subgroups of the idiopathic inflammatory myopathies. Arthritis Rheum. 58, 3239\u20133246 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrneurol201163_CR161","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.1002\/art.24039","volume":"58","author":"G Mamyrova","year":"2008","unstructured":"Mamyrova, G. et al. Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis. Arthritis Rheum. 58, 3941\u20133950 (2008).","journal-title":"Arthritis Rheum."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.63","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneurol.2011.63.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T01:15:03Z","timestamp":1741223703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneurol.2011.63"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":161,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["BFnrneurol201163"],"URL":"https:\/\/doi.org\/10.1038\/nrneurol.2011.63","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}